Kornimate/medical-research-clean huggingface dataset:
optimal amount of zinc to include in a lipid-based nutrient supplement (lns)

Conditions: Malnutrition

Summary: to assess zinc-related biochemical and functional responses among young burkinabe children with a presumed high risk of zinc deficiency who receive micronutrient products containing different amounts of zinc, provided with or between meals.

young healthy children will be identified by periodic consensus in the study area. 3200 infants meeting a set of eligibility criteria will be randomly assigned to receive lipid-based nutrient supplements (lns) with different amounts of zinc and a placebo or zinc supplement from 9 to 18 months of age. the families will receive the respective supplement at weekly intervals and the participants undergo a morbidity evaluation weekly, anthropometric evaluation at 9, 12, 15 and 18 months and laboratory analyses at enrollment and at 18 months of age. growth outcomes will be analyzed during the two-year follow up at 24, 30, 36 and 42 months of age.

Eligibility criteria:
inclusion criteria: * 9.0 to 9.9 mo of age exclusion criteria: * severe anemia * severely malnourished * presence of bipedal oedema * severe illness * congenital abnormalities * chronic medical condition * known hiv infection of mother or infant * history of peanut allergy * history of anaphylaxis or serious allergic reaction to any substance

Keywords: point-of-use fortification zinc supplement lipid-based nutrient supplement zinc deficiency micronutrient deficiency anemia
an exploratory study on the application of transarterial ct angiography in the interventional treatment of massive hemoptysis

Conditions: Hemoptysis

Summary: this is a single-arm, exploratory study to evaluate the value of transarterial ct angiography applying nexaris angio-ct in the interventional treatment of massive hemoptysis


Eligibility criteria:
inclusion criteria: * patients with massive hemoptysis（defined as more than 100ml per session or more than 300ml/day or with acute respiratory failure requiring mechanical ventilation or hemodynamic instability (systolic blood pressure \< 90 mmhg), regardless of hemoptysis amount） exclusion criteria: * pregnancy * patients with a previous history of bronchial artery embolization * uncorrectable severe infection, coagulation dysfunction, organ failure or cachexia, severe contrast agent allergy, and other interventional treatment contraindications
toward thriving: a set of reflective tools to empower chronic pain patients and help them envision a personal path to thriving.

Conditions: Chronic Pain

Summary: the purpose of this study is to introduce and test the usefulness of a reflective process meant to empower people with chronic pain and help support participant's resiliency and thriving. the study team hypothesizes that: -greater or equal to 80 percent of participants will report that the intervention was relatively easy to understand after orientation, low burden, potentially effective, and will have completed at least 2 of the 3 reflective tools.


Eligibility criteria:
inclusion criteria: * persistent or recurrent pain lasting longer than 3 months * able to read and write english exclusion criteria: * cancer (history of any bone-related cancer or cancer that metastasized to the bone; currently in treatment for any cancer or plan to start cancer treatment in the next 12 months; history of any cancer treatment in the last 24 months) * active substance abuse * uncontrolled depression or psychosis * visual or hearing difficulties that would preclude participation * individuals started receiving disability or compensation within the past year, or currently involved in litigation * current/planned (in the next 2 years) enrollment in another study of a device or investigational drug that would interfere with this study, this may include participation in a blinded trial. * any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators. this would include but not be limited to severe psychiatric disorders, active suicidal ideations or history of suicide attempts, and an uncontrolled drug and/or alcohol addiction)

Keywords: positive psychology intervention
prospective observational study on outcome of high-precision hypo-fractionated radiotherapy in metastatic breast cancer (precise-m)

Conditions: Breast Cancer; Metastatic Breast Cancer; Radiation Therapy Complication

Summary: this study is a prospective observational study on outcomes of high precision hypo-fractionated radiotherapy in breast cancer with distant metastasis.


Eligibility criteria:
inclusion criteria: * histologically confirmed breast cancer * presence of distant metastasis * radiation therapy using imrt, sbrt, or proton therapy is done or planned * able and willing to comply with the study protocol exclusion criteria: * unable to adhere to the study protocol
effect of interferential electrical stimulation on pain perception and disability level on interstitial cystitis

Conditions: Interstitial Cystitis

Summary: a total of 40 volunteers women with a diagnosis of interstitial cystitis. their ages ranged from 25 to 40 years old; their body mass index was \> 30 kg/m2 and were randomly assigned to a group (a) received interferential current at the lower abdomen, and also received traditional medicine or group (b) received traditional medicine for 8 successive weeks. both of the groups received the treatment program for 8 successive weeks. assessment of pain perception and disability level for all patients in both groups (a\&b) were done through visual analogue scale, o'leary-sant symptom index or interstitial cystitis index (icsi) and blood cortisol concentration were done before and after the treatment program.

forty volunteers women diagnosed clinically by gynecologist as painful bladder syndrome were participated in this study. they were selected randomly from the gynecological outpatient clinic, at al-zahra universal hospital, al azhar university, their ages ranged from 25 to 40 years and their body mass index was \> 30 kg/m2. all participants complain from suprapubic pain related to bladder filling, accompanied by other symptoms such as increased daytime and night-time frequency. exclusion criteria of the study were as follows: participant who had acute viral disease, acute tuberculosis and mental disorders, benign or malignant tumors of the pelvic region, participant who had active endometriosis or having artificial pacemaker or cardiac arrhythmia, participant who had sensory disturbances. participants were assigned randomly used sealed envelope into two groups (a\&b) equally in number. group (a): consisted of twenty patients suffering from painful bladder syndrome. they received interferential current at the lower abdomen, and also received traditional medicine (they were administered anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks. group (b): consisted of twenty patients suffering from painful bladder syndrome. they received traditional medicine (they were administered anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks

Eligibility criteria:
inclusion criteria: * their ages ranged from 25 to 40 years. * their body mass index was \> 30 kg/m2 exclusion criteria: * participant who had acute viral disease. * acute tuberculosis * mental disorders. * benign or malignant tumors of the pelvic region
impact of periodontal treatment on growth differentiation factor-15 levels

Conditions: Periodontal Diseases

Summary: in light of the controversy that are already approved but that however still exists regarding the efficacy and influence the management of periodontitis, the aim of this study was to evaluates, at 6-months follow-up, the post-treatment clinical and serum parameters in patients with periodontitis, treated by either full mouth scaling and root planing (fm-srp) treatment versus conventional oral hygiene treatment on serum crp and growth differentiation factor-15 levels.

this trial was conducted in accordance with the world medical association's declaration of helsinki of 1975, and reviewed in 2016. the local ethical committee approved the study protocol and each patient was carefully informed about the possible inherent risks of the study and provided their informed written consent. subjects with a diagnosis of periodontitis were enrolled in this clinical trial. the inclusion criteria were: 1) good condition of general health, 2) a minimum of 2 teeth for each quadrant with a pocket depth (pd) ranging from 4-6 mm, 3) no involvement of the furcation, 4) a minimum of six teeth per quadrant, respectively. the exclusion criteria were: 1) periodontal therapy during the last 12 months, 2) assumption of antibiotics during the last 6 months, 3) pregnancy, 4) any systemic condition which might affect the effects of the study treatment, 5) previous or current radiation or immunosuppressive therapies, 5) use of mouthwash containing antimicrobials during the previous 3 months, 6) no use of hormonal contraceptives, 7) medication by anti-inflammatory and immunosuppressive drugs, 8) previous history of hard-drinking, 9) smoking, 10) class ii and iii tooth mobility. patients randomly undergo to full mouth srp or quadrant srp

Eligibility criteria:
inclusion criteria: * good condition of general health * a minimum of 2 teeth for each quadrant with * pocket depth (pd) ranging from 4-6 mm * no involvement of the furcation * a minimum of a six teeth per quadrant, respectively exclusion criteria: * periodontal therapy during the last 12 months * assumption of antibiotics during the last 6 months * pregnancy * any systemic condition which might affect the effects of the study treatment * previous or current radiation or immunosuppressive therapies * use of mouthwash containing antimicrobials during the previous 3 months * no use of hormonal contraceptives * medication by anti-inflammatory and immunosuppressive drugs * previous history of hard drinking * smoking * class ii and iii tooth mobility
relation among hdl functionality, neoatherosclerosis and target lesion revascularization

Conditions: Coronary Artery Disease Progression

Summary: the aim of this study is to evaluate the relation among cholesterol uptake capacity which measure hdl functionality, neoathrosclerosis and target-lesion revascularization.

intracoronary stent implantation has markedly reduced the incidence of restenosis in patients with coronary artery disease. however, in-stent restenosis requiring target-lesion revascularization (tlr) occurs even with the use of drug-eluting stents. emerging evidence suggests that among various potential risk factors, atherogenic progression within the neointima, "neoatherosclerosis" is one of the major contributors to tlr, and that patients' lipid profile is one of the key risk factors for the development of neoatherosclerosis. conversely, recent animal and human studies have demonstrated the importance of high-density lipoprotein (hdl) functionality, rather than of hdl-cholesterol levels, in the development of de novo coronary artery disease. cholesterol efflux capacity, a measure of the ability of hdl to promote cholesterol removal from lipid-laden macrophages, was found to be inversely correlated with the incidence of cardiovascular events and was shown to improve cardiovascular risk prediction beyond that with the use of traditional coronary risk factors. therefore, the investigators hypothesized that the hdl function of promoting cholesterol removal from lipid-laden macrophages could be associated with tlr through its effect on the process of neoatherosclerosis progression within stents. recently, the investigators developed a rapid cell-free assay system to directly evaluate the capacity of hdl to accept additional cholesterol; the measurement of this cholesterol uptake capacity (cuc) enables hdl functionality to be readily evaluated in our daily practice. thus, the investigators performed this study in order to clarify the potential relationship among cuc, neoatherosclerosis, and tlr by using the novel cell-free assay system, cuc measurement, and optical coherence tomography (oct) analysis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of coronary artery disease * patients who had undergone percutaneous coronary intervention * patients who had been treated with bare-metal stents, drug-eluting stents * patients who had successfully undergone follow-up oct for the target stents \>6 months after stenting. exclusion criteria: * the stent was implanted in the left main trunk * oct images were of insufficient quality

Keywords: neoatherosclerosis cholesterol uptake capacity
safety and feasibility study of the chartis system with heterogeneous emphysema prior to endobronchial lung volume reduction (elvr)

Conditions: Heterogeneous Emphysema

Summary: the purpose of this study is to evaluate the safety and feasibility of the chartis system in measuring air flow and pressures in isolated lung compartments in emphysema patients prior to endobronchial lung volume reduction (elvr).


Eligibility criteria:
inclusion criteria: * heterogeneous emphysema as determined by high-resolution ct scan * scheduled for clinically indicated elvr procedure exclusion criteria: * hyperexcretive chronic bronchitis or excessive sputum secretion * active pulmonary infection * active asthma or lung hyper-responsiveness

Keywords: emphysema endobronchial lung volume reduction
bevacizumab intravitreal for myopic choroidal neovascularization

Conditions: Myopic Choroidal Neovascularization

Summary: to evaluate the clinical results of anti-vegf intra-vitreal injections (ivt) in cnv secondary to pathologic myopia (pm-cnv).

nineteen consecutive patients (19 eyes) with subfoveal pm-cnv, 18 of whom had been unsuccessfully treated with visudyne pdt, were treated with ivt of 1.25 mg bevacizumab or 0.5mg ranibizumab. etdrs best corrected visual acuity, macular thickness on oct scans, and angiographic features were recorded and evaluated. the aspect of oct scans passing across the pm-cnv was also analyzed. ivts were repeated only in case of persistent angiographic leakage and if oct scans showed retinal thickening or edema and serous retinal detachment. the follow-up period was at least 6 months.

Eligibility criteria:
inclusion criteria: * myopic cnvm, exclusion criteria: * patients with poor compliance * patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of stroke or myocardial infraction (\< one year). (physician clearance was obtained for all patients). * age related macular degeneration with juxtafoveal and subfoveal cnvm: recurrent cnvm following pdt and ttt with ivta. patient who could not afford pdt, macugen or lucentis which is fda approved. * patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery. * refractory macular oedema due to vein occlusion, pseudophakia, clinically significant macular oedema (csme) etc. that affects vision and does not respond adequately to usual treatment methods. * proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with pdr. * idiopathic cnvm, inflammatory cnvm and other conditions associated with cnvm.

Keywords: bevacizumab myopia complications neovascularization oct
melatonin and its effect on the perioperative opioid needs in pediatric patients undergoing laparoscopic surgery.

Conditions: Postoperative Pain

Summary: to study the role of preoperative melatonin adminsteration in pediatric patients undergoing laparoscopic surgeries regarding its analgesic and sedative effects


Eligibility criteria:
inclusion criteria: * age from 2 to 10 years. * sex: both sexes. * patients with asa classificaion i and ii. exclusion criteria: * declining to give written informed consent. * history of allergy to the medications used in the study. * psychiatric disorder. * asa classification iii-v. * fever ,cough , asthma or upper respiratory tract infection, neuromuscular disorders, spine abnormalities. * anticipated difficult airway . * history of malignant hyperthermia
evaluation of prochymal® adult human stem cells for treatment-resistant moderate-to-severe crohn's disease

Conditions: Crohn's Disease

Summary: protocol 603 is enrolling subjects with moderate-to-severe crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. the protocol investigates the safety and efficacy of using prochymal® adult human stem cells to induce remission. prochymal is delivered through a vein in the arm four times over two weeks, for approximately an hour each time.

a significant number of individuals with crohn's disease do not find relief with existing steroidal, immunosuppressive, or biologic therapies, and are forced to seek surgery or other drastic measures for treatment. prochymal® adult human stem cells are manufactured from healthy, volunteer donors, extensively tested, and are stored to be available as needed. human and animal studies have shown that the cells do not require any donor-recipient matching. the cells may have both immunosuppressive and healing benefits in crohn's disease. the cells naturally migrate specifically to sites of inflammation, so their effects are believed to be local and self-limiting rather than systemic. protocol 603 is enrolling subjects to evaluate the ability of prochymal to induce remission in subjects with moderate-to-severe disease (crohn's disease activity index -- cdai -- of between 250 and 450, inclusive) who have failed or been intolerant of at least one drug in each of the steroid, immunosuppressant, and biologic classes.

Eligibility criteria:
inclusion criteria: * failed (within last 2 yr) or intolerant of at least one steroid and at least one immunosuppressant and at exactly one biologic * cdai between 250 and 450, inclusive * endoscopically or radiographically confirmed crohn's disease of ileus or colon or both * c-reactive protein test (crp) of at least 5 mg/l (0.5 mg/dl)\*or\* cdai of at least 300 * weight between 40 and 150 kg, inclusive * adequate renal function * negative tuberculosis skin (ppd) test (or evaluated low risk of tb activation) exclusion criteria: * hiv or hepatitis infection active * allergy to ct contrast agents, or to bovine or porcine products * symptomatic fibrostenotic crohn's disease * permanent ostomy * biologic therapy within past 90 d * prednisone greater than 20 mg/d within past month * short-bowel syndrome * total parenteral nutrition * abnormal liver function * malignancy active within past 5 years (except completely resected basal or squamous cell carcinoma of skin) * enteric pathogens, including c. difficile * history of colonic mucosal dysplasia * current or prior evidence of tuberculosis (tb) (unless risk of activation or re-activation deemed low)

Keywords: crohn's disease adult stem cell therapy
study evaluating liver transplantation in haemophilia patients in spain

Conditions: Hemophilia; Hemophilia B

Summary: this study will analyze survival and outcome of patients with severe haemophilia who undergo liver transplantation in spain

probability sample

Eligibility criteria:
inclusion criteria: * patients with haemophilia who underwent liver transplantation and who have been followed-up at any site in spain. exclusion criteria: * patients without informed consent form.
diffusion weighted mri accuracy in cholesteatoma localization

Conditions: Cholesteatoma

Summary: magnetic resonance imaging of the middle ear has an increasing place in the therapeutic strategy in otology and especially for cholesteatoma. it is currently performed for complicated cholesteatomas and as part of the follow-up of operated patients to detect a recurrence or a cholesteatoma residue (alternative of choice to "second look" surgery). some people take ct and mri fusion to improve the localization of cholesteatoma. many studies have investigated the diagnostic capabilities of mri but very few have demonstrate their reliability in location diagnosis. the aim of the study was to propose a topographic reading method of the mri of the middle ear and to evaluate the performances in the localization of the cholesteatoma in order to adapt the surgical management


Eligibility criteria:
inclusion criteria * age: from 1 month and up * sex: man / woman * patient who had a tympanoplasty in closed technique, for the first surgical time of a cholesteatoma or for residual or recurrent cholesteatoma, performed by the same radiologist (pr anne charpiot) with the following characteristics: * code of the common classification of medical acts (ccam) * exeresis of cholesteatoma with tympanoplasty in closed technique and ossiculoplasty (cbfa002) * exeresis of cholesteatoma with tympanoplasty in closed technique (cbfa006) * exeresis of cholesteatoma confined to the tympanic cavity without antro-attic exploration (cbfa005) * tympanoplasty in closed technique with posterior tympanotomy (cbmd001) * secondary tympanoplasty in closed technique (cbmd002) * diagnostic code of the international classification of diseases (icd10) * cholesteatoma of the middle ear (h71) * diagnosis of macroscopic and / or pathological cholesteatoma. * preoperative diagnosis of cholesteatoma on mri of the middle ear performed in less than 6 months by the same radiologist (pr francis veillon). * subject (or the holders of parental authority in the case of minors) having agreed to the use of medical data for the purpose of this research. cholesteatoma is a very common disease in the pediatric population, with important functional issues, whose treatment is surgical. that's why our study includes minor subjects. criteria of non-inclusion * refusal of the patient to participate in the study * absence of data concerning the diagnosis and / or localization of cholesteatoma on the operative record * subject under the protection of justice * subject under guardianship or curatorship * pregnancy (woman of childbearing age) * breastfeeding

Keywords: diffusion weighted mri cholesteatoma localization